Lunai Bioworks Inc. (LNAI)
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Lunai Bioworks Inc.
OTC:LNAIOTC (delisted from Nasdaq, Form 25 effective Nov 12, 2026)Healthcare · Biotechnology
Mkt Cap$830K
EV-
Float4.88M
O/S5.03M
VOL1.27M sh
$ Vol$195K
RVOL0.86×
Inst Own3.8%
SI0.4%
Net Cash/Sh-
Dilution
MCap$830KFloat4.88MO/S5.03M
Dilution
| Form | Description | Links | |
|---|---|---|---|
| 15-12G | |||
| 8-K | |||
| 25 | |||
| EFFECT | |||
| S-8 POS | |||
| POS AM | |||
| S-8 POS | |||
| 8-K | |||
| 13D/A | |||
| 10-K | |||
| 8-K | |||
| NT 10-K | |||
| 13G | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 10-Q | |||
| 8-K | |||
| 8-K/A | |||
| DEFR14A | |||
| 8-K | |||
| 8-K | |||
| DEFA14A | |||
| DEFR14A | |||
| DEF 14A |
1-25 of 601 filings
…
Recent SEC filings with analysis
- 8-KLunai Bioworks voluntarily filed a Form 25 on November 2, 2026 to delist its common stock (LNAI) from Nasdaq, with the delisting expected effective on or about…
- 8-KLunai Bioworks (Nasdaq: LNAI) received a Nasdaq determination on October 21, 2026 that it no longer complies with the $2.5 million minimum stockholders' equity…
- 10-KLunai Bioworks (Nasdaq: LNAI) filed its fiscal 2026 10-K with substantial doubt about its ability to continue as a going concern.